Fennec Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Revenue	44.64	47.54	21.25
Revenue Growth (YoY)	-6.09%	123.69%	-
Cost of Revenue	3.76	3.18	1.26
Gross Profit	40.88	44.35	19.99
Selling, General & Admin	46.91	41.48	32.71
Research & Development	0.25	0.31	0.06
Total Operating Expenses	47.16	41.79	32.76
Operating Income	-6.28	2.57	-12.77
Interest Income	0.79	1.68	0.44
Interest Expense	-2.08	-4.07	-3.39
Other Non-Operating Income (Expense)	-2.06	-0.25	-0.32
Total Non-Operating Income (Expense)	-3.35	-2.64	-3.27
Pretax Income	-9.64	-0.07	-16.05
Provision for Income Taxes	0.11	0.37	-
Net Income	-9.74	-0.44	-16.05
Net Income to Common	-9.74	-0.44	-16.05
Shares Outstanding (Basic)	29	27	27
Shares Outstanding (Diluted)	29	27	27
Shares Change (YoY)	4.70%	2.71%	-
EPS (Basic)	-0.34	-0.02	-0.60
EPS (Diluted)	-0.34	-0.02	-0.60
Shares Outstanding	34.16	27.53	26.36
Free Cash Flow	-12.47	26.98	-17.14
Free Cash Flow Per Share	-0.44	0.99	-0.65
Gross Margin	91.57%	93.30%	94.08%
Operating Margin	-14.07%	5.40%	-60.09%
Profit Margin	-21.82%	-0.92%	-75.50%
FCF Margin	-27.94%	56.75%	-80.67%
EBITDA	-6.28	2.57	-12.77
EBIT	-6.28	2.57	-12.77
EBIT Margin	-14.07%	5.40%	-60.09%
Effective Tax Rate	-1.10%	-514.09%	0.00%

Updated Mar 24, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q